Near-final height in patients with congenital adrenal hyperplasia treated with combined therapy using GH and GnRHa
Autor(a) principal: | |
---|---|
Data de Publicação: | 2011 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Arquivos Brasileiros de Endocrinologia & Metabologia (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302011000800023 |
Resumo: | INTRODUCTION: Intrinsic limitations of glucocorticoid therapy in patients with congenital adrenal hyperplasia (CAH) determine frequent loss in final height. The association of secondary central precocious puberty and early epiphyseal fusion is also frequent. In these conditions, GnRHa treatment alone or in combination with GH has been indicated. OBJECTIVES: This is a retrospective study, describing the estatural findings of CAH patients with significant decrease in height prediction, who were submitted to combined GH plus GnRHa therapy up to near-final height. SUBJECTS AND METHODS: We studied 13 patients, eight females and five males, eight with the classical and five with the nonclassical form of the disorder. Treatment with hydrocortisone (10-20 mg/m²/day) or prednisolone (3-6 mg/kg/day) was associated with GnRHa (3.75 mg/months) for 4.0 (1.5) years, and GH (0.05 mg/kg/day) for 3.6 (1.4) years. RESULTS: Stature standard deviation score for bone age improved significantly after GH treatment, becoming similar to target height at the end of the second year of GH treatment. CONCLUSION: We conclude that combined GH plus GnRHa therapy can be useful in a subset of CAH patients with significant reduction of predicted final height associated with poor hormonal control and central precocious puberty. |
id |
SBEM-2_9c3848838b615f11f2229aeb04fe766f |
---|---|
oai_identifier_str |
oai:scielo:S0004-27302011000800023 |
network_acronym_str |
SBEM-2 |
network_name_str |
Arquivos Brasileiros de Endocrinologia & Metabologia (Online) |
repository_id_str |
|
spelling |
Near-final height in patients with congenital adrenal hyperplasia treated with combined therapy using GH and GnRHaGHGnRHacongenital adrenal hyperplasiaheightgrowth recoveryINTRODUCTION: Intrinsic limitations of glucocorticoid therapy in patients with congenital adrenal hyperplasia (CAH) determine frequent loss in final height. The association of secondary central precocious puberty and early epiphyseal fusion is also frequent. In these conditions, GnRHa treatment alone or in combination with GH has been indicated. OBJECTIVES: This is a retrospective study, describing the estatural findings of CAH patients with significant decrease in height prediction, who were submitted to combined GH plus GnRHa therapy up to near-final height. SUBJECTS AND METHODS: We studied 13 patients, eight females and five males, eight with the classical and five with the nonclassical form of the disorder. Treatment with hydrocortisone (10-20 mg/m²/day) or prednisolone (3-6 mg/kg/day) was associated with GnRHa (3.75 mg/months) for 4.0 (1.5) years, and GH (0.05 mg/kg/day) for 3.6 (1.4) years. RESULTS: Stature standard deviation score for bone age improved significantly after GH treatment, becoming similar to target height at the end of the second year of GH treatment. CONCLUSION: We conclude that combined GH plus GnRHa therapy can be useful in a subset of CAH patients with significant reduction of predicted final height associated with poor hormonal control and central precocious puberty.Sociedade Brasileira de Endocrinologia e Metabologia2011-11-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302011000800023Arquivos Brasileiros de Endocrinologia & Metabologia v.55 n.8 2011reponame:Arquivos Brasileiros de Endocrinologia & Metabologia (Online)instname:Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)instacron:SBEM10.1590/S0004-27302011000800023info:eu-repo/semantics/openAccessLongui,Carlos AlbertoKochi,CristianeCalliari,Luís Eduardo ProcópioModkovski,Maria Barcellos RosaSoares,MarisaAlves,Érica FerreiraPrudente,Fernanda Vilas BoasMonte,Osmareng2012-01-03T00:00:00Zoai:scielo:S0004-27302011000800023Revistahttps://www.aem-sbem.com/ONGhttps://old.scielo.br/oai/scielo-oai.php||abem-editoria@endocrino.org.br1677-94870004-2730opendoar:2012-01-03T00:00Arquivos Brasileiros de Endocrinologia & Metabologia (Online) - Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)false |
dc.title.none.fl_str_mv |
Near-final height in patients with congenital adrenal hyperplasia treated with combined therapy using GH and GnRHa |
title |
Near-final height in patients with congenital adrenal hyperplasia treated with combined therapy using GH and GnRHa |
spellingShingle |
Near-final height in patients with congenital adrenal hyperplasia treated with combined therapy using GH and GnRHa Longui,Carlos Alberto GH GnRHa congenital adrenal hyperplasia height growth recovery |
title_short |
Near-final height in patients with congenital adrenal hyperplasia treated with combined therapy using GH and GnRHa |
title_full |
Near-final height in patients with congenital adrenal hyperplasia treated with combined therapy using GH and GnRHa |
title_fullStr |
Near-final height in patients with congenital adrenal hyperplasia treated with combined therapy using GH and GnRHa |
title_full_unstemmed |
Near-final height in patients with congenital adrenal hyperplasia treated with combined therapy using GH and GnRHa |
title_sort |
Near-final height in patients with congenital adrenal hyperplasia treated with combined therapy using GH and GnRHa |
author |
Longui,Carlos Alberto |
author_facet |
Longui,Carlos Alberto Kochi,Cristiane Calliari,Luís Eduardo Procópio Modkovski,Maria Barcellos Rosa Soares,Marisa Alves,Érica Ferreira Prudente,Fernanda Vilas Boas Monte,Osmar |
author_role |
author |
author2 |
Kochi,Cristiane Calliari,Luís Eduardo Procópio Modkovski,Maria Barcellos Rosa Soares,Marisa Alves,Érica Ferreira Prudente,Fernanda Vilas Boas Monte,Osmar |
author2_role |
author author author author author author author |
dc.contributor.author.fl_str_mv |
Longui,Carlos Alberto Kochi,Cristiane Calliari,Luís Eduardo Procópio Modkovski,Maria Barcellos Rosa Soares,Marisa Alves,Érica Ferreira Prudente,Fernanda Vilas Boas Monte,Osmar |
dc.subject.por.fl_str_mv |
GH GnRHa congenital adrenal hyperplasia height growth recovery |
topic |
GH GnRHa congenital adrenal hyperplasia height growth recovery |
description |
INTRODUCTION: Intrinsic limitations of glucocorticoid therapy in patients with congenital adrenal hyperplasia (CAH) determine frequent loss in final height. The association of secondary central precocious puberty and early epiphyseal fusion is also frequent. In these conditions, GnRHa treatment alone or in combination with GH has been indicated. OBJECTIVES: This is a retrospective study, describing the estatural findings of CAH patients with significant decrease in height prediction, who were submitted to combined GH plus GnRHa therapy up to near-final height. SUBJECTS AND METHODS: We studied 13 patients, eight females and five males, eight with the classical and five with the nonclassical form of the disorder. Treatment with hydrocortisone (10-20 mg/m²/day) or prednisolone (3-6 mg/kg/day) was associated with GnRHa (3.75 mg/months) for 4.0 (1.5) years, and GH (0.05 mg/kg/day) for 3.6 (1.4) years. RESULTS: Stature standard deviation score for bone age improved significantly after GH treatment, becoming similar to target height at the end of the second year of GH treatment. CONCLUSION: We conclude that combined GH plus GnRHa therapy can be useful in a subset of CAH patients with significant reduction of predicted final height associated with poor hormonal control and central precocious puberty. |
publishDate |
2011 |
dc.date.none.fl_str_mv |
2011-11-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302011000800023 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302011000800023 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S0004-27302011000800023 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Endocrinologia e Metabologia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Endocrinologia e Metabologia |
dc.source.none.fl_str_mv |
Arquivos Brasileiros de Endocrinologia & Metabologia v.55 n.8 2011 reponame:Arquivos Brasileiros de Endocrinologia & Metabologia (Online) instname:Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) instacron:SBEM |
instname_str |
Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) |
instacron_str |
SBEM |
institution |
SBEM |
reponame_str |
Arquivos Brasileiros de Endocrinologia & Metabologia (Online) |
collection |
Arquivos Brasileiros de Endocrinologia & Metabologia (Online) |
repository.name.fl_str_mv |
Arquivos Brasileiros de Endocrinologia & Metabologia (Online) - Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) |
repository.mail.fl_str_mv |
||abem-editoria@endocrino.org.br |
_version_ |
1754734811732246528 |